scholarly journals Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence

2004 ◽  
Vol 113 (2) ◽  
pp. 259-266 ◽  
Author(s):  
Caroline L. Smith ◽  
P. Rod Dunbar ◽  
Fareed Mirza ◽  
Michael J. Palmowski ◽  
Dawn Shepherd ◽  
...  
Keyword(s):  
High Risk ◽  
Tumor Antigen ◽  
Disease Recurrence ◽  
Melanoma Tumor ◽  
Risk Of Disease ◽  
Melanoma Patients ◽  
Antigen Epitope

scholarly journals Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence

2012 ◽  
Vol 20 (5) ◽  
pp. 1056-1062 ◽  
Author(s):  
Alice Pinc ◽  
Rajasekharan Somasundaram ◽  
Christine Wagner ◽  
Marcus Hörmann ◽  
Georgios Karanikas ◽  
...  
Keyword(s):  
High Risk ◽  
Disease Recurrence ◽  
Risk Of Disease ◽  
Melanoma Patients

scholarly journals Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 181-189 ◽  
Author(s):  
Sarah Alexander
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
High Risk ◽  
Lymphoblastic Leukemia ◽  
Disease Recurrence ◽  
Cooperative Groups ◽  
Optimal Care ◽  
Disease Response ◽  
Improved Outcomes ◽  
Risk Of Disease ◽  
Outcomes For Children

Abstract For children with acute lymphoblastic leukemia, the identification of those at higher risk of disease recurrence and modifying therapy based on this risk is a critical component to the provision of optimal care. The specific definitions of high-risk ALL vary across cooperative groups, but the themes are consistent, being largely based on leukemia biology and disease response. Intensification of conventional chemotherapy for those with high-risk disease has led to improved outcomes. It is anticipated that the development of rational targeted therapy for specific biologically unique subsets of children with leukemia will contribute to ongoing progress in improving the outcomes for children with acute lymphoblastic anemia.

scholarly journals Imatinib as adjuvant therapy for high risk GIST: a case report

2015 ◽  
Vol 5 (4S) ◽  
pp. 7-12
Author(s):  
Patrizia Lista ◽  
Agostino Ponzetti
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Standard Dose ◽  
Abdominal Mass ◽  
Disease Recurrence ◽  
First Year ◽  
Radical Excision ◽  
Risk Of Disease ◽  
Exon 11 ◽  
Ct Finding

We here report a case of 42 years old man who experienced sudden abdominal cramps and then underwent explorative laparotomy because of the CT-finding of a 23 cm abdominal mass at the stomach. Frozen specimen analysis indicated a probable gastrointestinal stromal tumor (GIST). Radical excision was performed. Definitive pathological analysis revealed a CD34 and CD 117(c-KIT) positive GIST with a mitotic count of 15/50 HPF. These features indicate a disease with an high risk of recurrence within few years. Molecular analysis found a WK557-558 deletion of c-KIT exon 11, that indicates a poor prognosis in patients with completely resected GIST. In april 2010 he started adjuvant therapy with imatinib at standard dose of 400 mg/day that was well tolerated: he reported only G1 periocular edema and conjunctivitis. Considering the risk of disease recurrence he continued adjuvant therapy beyond the first year.

scholarly journals Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy

Children ◽  
2019 ◽  
Vol 6 (1) ◽  
pp. 5 ◽  
Author(s):  
Holly J. Meany
Keyword(s):  
High Risk ◽  
Prognostic Significance ◽  
Disease Recurrence ◽  
Disease Stage ◽  
Current Therapy ◽  
Mycn Gene ◽  
Risk Of Disease ◽  
Short And Long Term ◽  
Risk Categories

Neuroblastoma, a tumor of the sympathetic nervous system, is the most common extra-cranial neoplasm of childhood. Variables with prognostic significance in patients with neuroblastoma, including age at diagnosis, disease stage, tumor histology, MYCN gene amplification, tumor cell ploidy, and the presence of segmental chromosomal aberrations are utilized to classify patients based on risk of disease recurrence. Patients with non-high-risk neuroblastoma, low- and intermediate-risk categories, represent nearly half of all newly diagnosed cases. This group has an excellent event-free and overall survival with current therapy. Over time, the objective in treatment of non-high-risk neuroblastoma has been reduction of therapy intensity to minimize short- and long-term adverse events all the while maintaining excellent outcomes.

Pharmacological methods to reduce disease recurrence

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Charles Craddock
Keyword(s):  
High Risk ◽  
Antitumor Activity ◽  
Conditioning Regimen ◽  
Inverse Correlation ◽  
Disease Recurrence ◽  
Disease Relapse ◽  
Relapse Risk ◽  
Substantial Progress ◽  
Risk Of Disease ◽  
Conditioning Regimens

Abstract Allogeneic stem cell transplantation is an increasingly important treatment option in patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Although there has been substantial progress in reducing transplantation-related mortality (TRM), little progress has been made in reducing the risk of disease relapse, which continues to represent the major cause of treatment failure in patients allografted for AML and MDS. Experience with myeloablative conditioning regimens has demonstrated that, although intensification of the preparative regimen reduces relapse risk, any survival benefit is blunted by a concomitant increase in TRM. A similar inverse correlation between relapse risk and TRM is observed in patients allografted using a reduced-intensity conditioning regimen. However, the markedly lower toxicity of such regimens has permitted the design of novel conditioning strategies aimed at maximizing antitumor activity without excessive transplant toxicity. Coupled with recent advances in drug delivery and design, this has allowed the development of a spectrum of new conditioning regimens in patients with high-risk AML and MDS. At the same time, the optimization of a graft-versus-leukemia (GVL) effect by minimizing posttransplantation immunosuppression, with or without the infusion of donor lymphocytes, is essential if the risk of disease relapse is to be reduced. Recently, the delivery of adjunctive posttransplantation therapies has emerged as a promising method of augmenting antileukemic activity, either through a direct antitumor activity or consequent upon pharmacological manipulation of the alloreactive response. Taken together these advances present a realistic possibility of delivering improved outcome in patients allografted for high-risk AML or MDS.

471 MGMT Methylation As a Novel Biomarker for the Identification of Stage III Colorectal Cancers At High-Risk of Disease Recurrence Following Curative Surgery

2013 ◽  
Vol 144 (5) ◽  
pp. S-85 ◽  
Author(s):  
Yoshiko Mori ◽  
Takeshi Nagasaka ◽  
Hiroshi Tazawa ◽  
Yuzo Umeda ◽  
Tatsuya Morikawa ◽  
...  
Keyword(s):  
High Risk ◽  
Disease Recurrence ◽  
Stage Iii ◽  
Colorectal Cancers ◽  
Mgmt Methylation ◽  
Curative Surgery ◽  
Risk Of Disease
Sign in / Sign up

Export Citation Format

Share Document